diff --git a/entities/health/nct-semaglutide-cud-phase2-cbt.md b/entities/health/nct-semaglutide-cud-phase2-cbt.md
new file mode 100644
index 000000000..86c924831
--- /dev/null
+++ b/entities/health/nct-semaglutide-cud-phase2-cbt.md
@@ -0,0 +1,22 @@
+# Semaglutide + CBT for Cocaine Use Disorder (Phase 2)
+
+**Type:** Clinical trial  
+**Phase:** 2  
+**Status:** Recruiting (as of May 2026)  
+**Intervention:** Semaglutide combined with cognitive behavioral therapy (CBT)  
+**Population:** Adults with diagnosed cocaine use disorder and BMI ≥25  
+**Primary objective:** Reduce cocaine cravings and use  
+**Registry:** withpower.com/trial/phase-2-cocaine-related-disorders-10-2025
+
+## Timeline
+
+- **2025-10** — Trial opened for recruitment
+- **2026-05** — Actively recruiting participants
+
+## Context
+
+This trial follows the All of Us observational finding (Abegaz et al., March 2026) showing 75% lower odds of cocaine use disorder in GLP-1 users (OR=0.25). Cocaine use disorder has no FDA-approved pharmacotherapy, making this a high-priority unmet need. The trial combines semaglutide with CBT, reflecting the behavioral-biological integration model seen in other GLP-1 SUD trials.
+
+## Expected Results
+
+Phase 2 results anticipated 2027-2028.
\ No newline at end of file
diff --git a/entities/health/nct-semaglutide-cud-phase2-hiv.md b/entities/health/nct-semaglutide-cud-phase2-hiv.md
new file mode 100644
index 000000000..e0a4b85ef
--- /dev/null
+++ b/entities/health/nct-semaglutide-cud-phase2-hiv.md
@@ -0,0 +1,23 @@
+# Semaglutide for Cocaine Use Disorder in HIV Cohort (Phase 2)
+
+**Type:** Clinical trial  
+**Phase:** 2  
+**Status:** Recruiting (as of May 2026)  
+**Intervention:** Semaglutide vs. placebo  
+**Population:** Adults with cocaine use disorder, with and without HIV infection  
+**Primary objective:** Safety and effectiveness of semaglutide for CUD  
+**Special population rationale:** High CUD prevalence in HIV+ individuals; dual metabolic and addiction benefits  
+**Registry:** withpower.com/trial/phase-2-human-immunodeficiency-virus-hiv-infections-2-2025
+
+## Timeline
+
+- **2025-02** — Trial opened for recruitment
+- **2026-05** — Actively recruiting participants
+
+## Context
+
+This trial targets a high-need population where CUD prevalence is elevated and metabolic complications are common. The HIV-specific design provides real-world justification for off-label use even before CUD-specific approval. Follows All of Us observational signal (OR=0.25 for CUD in GLP-1 users).
+
+## Expected Results
+
+Phase 2 results anticipated 2027-2028.
\ No newline at end of file
diff --git a/inbox/queue/2026-05-08-glp1-cocaine-use-disorder-phase2-recruiting-2025.md b/inbox/archive/health/2026-05-08-glp1-cocaine-use-disorder-phase2-recruiting-2025.md
similarity index 98%
rename from inbox/queue/2026-05-08-glp1-cocaine-use-disorder-phase2-recruiting-2025.md
rename to inbox/archive/health/2026-05-08-glp1-cocaine-use-disorder-phase2-recruiting-2025.md
index dba808af0..390920fd2 100644
--- a/inbox/queue/2026-05-08-glp1-cocaine-use-disorder-phase2-recruiting-2025.md
+++ b/inbox/archive/health/2026-05-08-glp1-cocaine-use-disorder-phase2-recruiting-2025.md
@@ -7,10 +7,13 @@ date: 2025-01-01
 domain: health
 secondary_domains: []
 format: article
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-05-08
 priority: medium
 tags: [GLP-1, cocaine use disorder, substance use disorder, semaglutide, Phase 2 trial, addiction medicine, CUD]
 intake_tier: research-task
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content